Clinical trial NCT02260817: Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Official title: Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Metastatic Prostate Cancer
Keywords: Prostate Cancer
11C Choline
PET Imaging
Lead sponsor: Global Isotopes, LLC d/b/a Zevacor Molecular
Sponsor class: INDUSTRY
First posted: 2014-10-09
Enrollment: 109
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment.

The purpose of this study is to:

A. Provide expanded access the drug 11C-choline.

B. Determine the performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value) of 11C-choline PET/Computed Tomography (CT) and PET/Magnetic Resonance Imaging (MRI) in the detection of metastatic prostate cancer in patients with biochemical relapse of prostate cancer after primary treatment in a prospective manner.

C. Determine the optimal Prostate-Specific Antigen (PSA) trigger value in 11C-choline PET/CT and PET/MRI positive patients through a prospective study.

D. Determine factors that predict a confirmed positive 11C-choline PET/CT and PET/MRI using a multivariable analysis of clinical and pathologic data collected prospectively.

E. Compare the individual performance characteristics of 11C-choline PET/CT and 11C-choline PET/MRI and the combination of 11C-choline PET/CT and PET/MRI

Study Protocol:

1. Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan.
2. The CT and MRI images will be evaluated for evidence of metastatic prostate cancer.
3. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer.
4. Evidence of metastasis on conventional imaging or 11C-choline PET will be confirmed with biopsy or surgical pathology when possible, or by response to treatment on subsequent imaging.
5. Rates of confirmed metastasis between conventional CT and MRI images will be compared with the 11C-choline PET CT and MRI images.
6. Upon conclusion of each imaging protocol, the referring physician will receive written documentation of the results. At this time, the patient will be considered off study and no further follow up is required.

Detailed description: 1. The first arm of this study serves to provide expanded access to 11C-choline injection as currently defined under the reference listed drug label as an investigational drug in geographical service areas where 11C-choline is not available. The second arm expands access as well but also attempts to determine the more effective imaging modality and conditions between PET/CT and PET/MR.
2. The study will consist of patients who have a biochemical relapse or other evidence of relapse after primary treatment. The first arm of the study is open to as many patients who elect to participate in the study that are over the age of 18 and have experienced a biochemical relapse of prostate cancer after primary treatment. The second arm will consist of patients who have been treated with radiation therapy, or androgen suppression and radiation therapy who have a PSA \> 2 ng/mL higher than the nadir level. The nadir level in patients who have been treated with androgen suppression and radiation therapy is determined after the serum testosterone level has normalized. This study group will also consist of patients who have been treated with radical prostatectomy and who have a biochemical relapse defined as a PSA of 0.2 ng/mL confirmed at that level or higher on a subsequent PSA test 3 months later. This group may consist of men who have other clinical evidence of relapse such as a suspicious bone scan or CT scan regardless of PSA kinetics. Patients identified as potential subjects will be screened against the eligibility criteria as defined above in Section 5.1.
3. Informed consent will be obtained from all participants before any study related procedures are conducted. Each participant will be informed about the nature of the study, its purpose, and possible risks. Informed consent will be documented by using the written informed consent document approved by the local IRB at the Decatur Memorial Hospital.
4. At the time of referral, patients will be asked to bring their prior records as it pertains to their prostate cancer history. Data collected from outside records, such as radiographic studies, previous imaging studies and biopsies will be incorporated into the study record.
5. Abstracted data for the study record will include:

   1. Patient demographics such as age, race, and family history of prostate cancer
   2. Risk factors such as finasteride or dutasteride use, and environmental exposure (eg. Agent orange)
   3. Prostate exam results, most recent within last 90 days
   4. PSA test results, most current and past
   5. Past medical and surgical history
   6. Current medications
   7. Allergies
   8. Pathology reports
   9. Imaging reports
   10. Date of diagnosis
   11. Date(s) of biochemical relapse and coordinating PSA results. Once all records have been assessed for eligibility, an order for the 11C-choline PET CT scan and MRI scan will be requested from the referring physician and patient will be scheduled and given the appropriate prep instructions.
6. Both arms of the study will undergo a 11C-choline PET CT scan and MRI scan. The CT scan will be performed with intravenous contrast unless deemed unsafe by lab values. The CT and MRI images will be evaluated for evidence of metastatic prostate cancer. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Unequivocal evidence of metastasis on both conventional imaging and 11C-choline PET will be considered a true positive. Evidence of metastasis on conventional imaging or 11C-choline PET will be confirmed with biopsy or surgical pathology when possible, or by response to treatment on subsequent imaging. If confirmation of metastasis is not achievable by biopsy or surgical pathology, then confirmation will be achieved with 11C-choline PET CT and MRI images obtained 3 months after treatment conclusion. Rates of confirmed metastasis between conventional CT and MRI images will be compared with the 11C-choline PET CT and MRI images.
7. Upon conclusion of each imaging protocol, the referring physician will receive written documentation of the results. At this time, the patient will be considered off study and no further follow up is required.

Eligibility criteria: Inclusion Criteria:

1. For biochemical relapse after primary treatment

   1. PSA \> 0.2 ng/ml after radical prostatectomy confirmed at that level or higher on a subsequent test 3 months later
   2. PSA increase \>2 ng/ml from nadir following radiation therapy
   3. PSA increase \>2 ng/ml from nadir following radiation therapy plus androgen deprivation therapy with nadir defined with normalized testosterone level
   4. Two consecutive PSA increases from nadir level after androgen blockade or androgen suppression therapy
2. Kidney function with GFR \> 60 mL/sec/1.73m2 and Creatinine \< 1.7mg, collected within 90 days of planned scan

   1. if GFR is \> or equal to 60 mL/sec/1.73m2, PET/CT will be completed with contrast
   2. if GFR is \< 60 mL/sec/1.73m2, PET/CT will be completed without contrast
   3. if Creatinine is \> than 1.7 mg, Radiology will follow ACR recommendations as outlined in department policy.
3. No known allergy to iodinated radiologic contrast media
4. Able to have MRI based on screening evaluation. If patient is found to be MRI incompatible, the 11C-choline PET/MRI portion of the study will not be completed. Please see the provided contact numbers for further options.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

Exclusion Criteria:

1. ECOG Performance Status \> 2.
2. Concurrent malignancy, i.e. colon cancer.
3. Treatment for another malignancy except superficial skin cancer within 5 years

Primary outcomes:
measure: Evidence of Metastatic Prostate Cancer
timeFrame: After 11C-choline PET CT scan and MRI scans, approximately 1 day. If surgery or response to treatment required to evaluate, approximately 1 to 3 months.
measure: Sensitivity of 11C Choline PET Imaging Scans
timeFrame: Approximately 1 day post-scan for patient results
measure: Specificity of 11C Choline PET Imaging Scans
timeFrame: Approximately 1 day post-scan for patient results
measure: Positive Predictive Value (PPV) of 11C Choline PET Imaging Scans
timeFrame: Approximately 1 day post-scan for patient results
measure: Negative Predictive Value (NPV) of 11C Choline PET Imaging Scans
timeFrame: Approximately 1 day post-scan for patient results
measure: Count of Participants With Positive or Negative PET, CT, or MRI Modalities Resulting in Prostate Cancer (PCa) Confirmation
timeFrame: Approximately 1 day post-scan for patient results
Secondary outcomes:
measure: Median Age at Primary Treatment
timeFrame: The participants' age at primary treatment was collected upon study enrollment (approximately 1 week into study)
measure: Median PSA at Diagnosis of Arm 2 Participants
timeFrame: The participants' primary PSA at diagnosis was collected upon study enrollment (approximately 1 week into study)
measure: Clinical T (cT) Stage of Arm 2 Participants
timeFrame: The participants' clinical stage data was collected upon study enrollment (approximately 1 week into study)
measure: Median Primary Biopsy Gleason Score of Arm 2 Participants
timeFrame: The participants' primary Biopsy Gleason Score data was collected upon study enrollment (approximately 1 week into study)
measure: Primary Treatment Modality of Arm 2 Participants
timeFrame: The participants' primary treatment data was collected upon study enrollment (approximately 1 week into study)
measure: Pathological Stage (pT) of Prostate Cancer (PC) of Arm 2 Participants
timeFrame: The participants' primary pathological staging data was collected upon study enrollment (approximately 1 week into study)
measure: Primary Surgical Margins of Arm 2 Participants
timeFrame: The participants' primary surgical margins data was collected upon study enrollment (approximately 1 week into study)
measure: Primary Positive Lymph Node Ratio of Arm 2 Participants
timeFrame: The participants' primary positive lymph note ratio was collected upon study enrollment (approximately 1 week into study)
measure: Additional Treatment and Type for Arm 2 Participants
timeFrame: The participants' additional primary treatment data was collected upon study enrollment (approximately 1 week into study)
measure: Median Months to Biochemical Relapse of Arm 2 Participants
timeFrame: The participants' biochemical relapse data was collected upon study enrollment (approximately 1 week into study)
measure: Median Age of Arm 2 Participant at PET Imaging
timeFrame: The participants' age at study entry was collected upon study enrollment (approximately 1 week into study)
measure: Median PSA of Arm 2 Participant at PET Imaging
timeFrame: The participants' PSA was collected upon study enrollment (approximately 1 week into study)
measure: Median PSA Doubling Time of Arm 2 Participants at PET Imaging
timeFrame: The participants' PSA doubling time was collected upon study enrollment (approximately 1 week into study)
measure: Median PSA Velocity of Arm 2 Participants at PET Imaging
timeFrame: The participants' PSA velocity was collected upon study enrollment (approximately 1 week into study)
measure: ADT (Androgen Deprivation Therapy) in Participant at PET Imaging
timeFrame: The participants' participation in ADT was collected upon study enrollment (approximately 1 week into study)
Other outcomes:
Locations:
city: Decatur
country: United States
facility: Decatur Memorial Hospital
state: Illinois
Study officials:
affiliation: Decatur Memorial Hospital
name: Thomas H Tarter, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: